Notably, several baseline characteristics may influence the efficacy of IL-17 inhibitors in patients with psoriasis (Hjort et al., 2024; Loft et al., 2022; Egeberg et al., 2024; Anghel et al., 2021). Here, IL17A is linked to psoriasis.